<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933906</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_CML 1</org_study_id>
    <secondary_id>2013-000115-24</secondary_id>
    <nct_id>NCT01933906</nct_id>
  </id_info>
  <brief_title>Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response</brief_title>
  <official_title>Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase I pilot study, it is planned to investigate the feasibility and safety of
      adding an interferon therapy to an preexisting imatinib treatment in patients with chronic
      phase chronic myeloid leukaemia. The participating patients have already reached a response
      during their imatinib therapy (CCyR) but have still a detectable disease (no molecular
      response MR 4.5 or better).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2013</start_date>
  <completion_date type="Actual">November 14, 2018</completion_date>
  <primary_completion_date type="Actual">November 14, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and seriousness of adverse events to evaluate safety and tolerability</measure>
    <time_frame>30 months</time_frame>
    <description>The primary objective is to determine the safety and tolerability of the addition of P1101 to the pre-study established dose of imatinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Number of patients achieving an improvement of remission status)</measure>
    <time_frame>30 months</time_frame>
    <description>Secondary objective is to determine the rate of achievement of ≥ 1 log reduction from the initial BCR-ABL transcript level at study entry and the achievement of molecular remission 4.5 or undetectable BCR-ABL transcripts.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Phase Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>P1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.
Maximum treatment duration will not expand 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P1101</intervention_name>
    <arm_group_label>P1101</arm_group_label>
    <other_name>PEG-Proline-Interferon alpha-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  BCR-ABL positive chronic myeloid leukaemia in chronic phase treated with imatinib as
             first line therapy

          -  CHR, CCyR after at least 18 months of imatinib treatment

          -  Adequate organ function, defined as the following:

               -  total bilirubin &lt; 1.5 x ULN,

               -  AST and ALT &lt; 2.5 x ULN,

               -  creatinine &lt; 1.5 x ULN,

               -  ANC &gt; 1.5 x 109/L,

               -  platelets &gt; 100 x 109/L

          -  Written, voluntarily signed informed consent

        Exclusion Criteria:

          -  CMR (molecular remission 4.5 or BCR-ABL transcripts undetectable)

          -  Patient has received any other investigational treatment within 28 days before study
             entry

          -  Treatment with a second generation tyrosine kinase inhibitor (dasatinib, nilotinib)

          -  ECOG performance status ≥ 3

          -  Patients with a primary of a different histological origin than the study indication
             (unless relapse-free interval is ≥ 5 years, except cervical carcinoma, basal cell
             epithelioma or squamous cell carcinoma of the skin)

          -  Evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated
             respiratory, cardiac, hepatic or renal disease etc.)

          -  Acute chronic infections

          -  Known autoimmune disease (e.g. collagen disease, polyarthritis, immune
             thrombocytopenia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune
             disorder)

          -  Female patients who are pregnant or breast-feeding

          -  Known diagnosis of HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Thaler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Wels-Grieskirchen GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Innsbruck, Univ.-Klinik f.Innere Medizin V Hämtologie u. Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz - Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der PMU Salzburg, Universitätsklinik für Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2013</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Chronic myeloid leukaemia</keyword>
  <keyword>PEG-Proline-Interferon-alpha 2b</keyword>
  <keyword>Interferon</keyword>
  <keyword>P1101</keyword>
  <keyword>Imatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

